skip to main content

brainstorm askiatroX medicines

simulations beta

loading page…

learn & practise

exams international doctors free questions Socratic Tutor rounds stat clinical connections academy journal tool guides

clinical reference

askiatroX knowledge centre medicines UK / NICE guidance international guidance calculators q&a library

trust & support

how it works methodology account & support frequently asked questions about us clinical safety consultancy

legal

mobile app · scan to download

Medicines amikacin sulfateQuestion & answer

amikacin sulfate · Medicine question

How common are nausea and vomiting with amikacin injection?

iatroX medicinesPublished 8 November 2026

The answer

Answer

Nausea and vomiting are uncommon with amikacin injection, affecting at least 1 in 1,000 but fewer than 1 in 100 people.

Sources for this answer

Amikacin 250 mg/ml InjectionHospira UK Ltd · emc · SmPC §4.8 Undesirable effects · Version 19Document updated 5 April 2024

Sources checked 8 November 2026

Explore this learning need in CPDTake this topic to CPD, then choose your learning context and available question library.

The full medicine guide

More questions about amikacin sulfate

At what temperature should the Hospira UK Ltd Amikacin 250 mg/ml Injection product be stored before first use?Can amikacin injection be given intramuscularly or intravenously?Can the Hospira UK Ltd Amikacin 250 mg/ml Injection product be physically mixed with other antibacterial agents in syringes or infusion bottles?Does darkening from colourless to pale yellow indicate a loss of potency in the Hospira UK Ltd Amikacin 250 mg/ml Injection product?How much sodium is in each 2 ml vial of the Hospira UK Ltd amikacin 250 mg/ml injection product?

amikacin sulfate

Read the wider context, including uses, precautions and the sources behind this medicine guide.

Read the amikacin sulfate guide

More clinical questions?

Explore the tools and reference material available on iatroX.

Explore askiatroX

Is amikacin injection contraindicated in patients with a known allergy to amikacin or its formulation components?